Alsina, Laia
Montoro, J. Bruno
Moral, Pedro Moral
Neth, Olaf
Pica, Marta Ortiz
Sánchez-Ramón, Silvia
Presa, María
Oyagüez, Itziar
Casado, Miguel Ángel
González-Granado, Luis Ignacio
Funding for this research was provided by:
Shire, a member of the Takeda group of companies
Universidad Complutense de Madrid
Article History
Received: 24 November 2020
Accepted: 1 September 2021
First Online: 21 September 2021
Declarations
:
: J. Bruno Montoro reports grants and consultant fees from Biotest, CSL Behring, Grifols, Octapharma, and Shire, a Takeda company, during the conduct of the study. Olaf Neth has been an invited speaker for CSL Behring, Grifols, and Shire, a Takeda company. Marta Ortiz Pica reports research grants and consultant fees from Shire, a member of the Takeda group of companies. Laia Alsina has been an invited speaker for Binding Site, CSL Behring, and Shire, a Takeda company. Luis Ignacio González-Granado has been an invited speaker for CSL Behring and Shire, a Takeda company. Silvia Sánchez-Ramón has served as speaker, consultant, and advisory board member for, or has received research funding from, Biotest, CSL Behring, Grifols, Octapharma, and Shire, a Takeda company. Itziar Oyagüez, Miguel Ángel Casado, and María Presa are employees of Pharmacoeconomics and Outcomes Research Iberia, a consultant company specialized in economic evaluation of health technologies, which has received unrestricted funding for development of the analysis. No funding has been received in relation with the authorship of the present manuscript. Pedro Moral Moral reports no competing interests.